Showing results (371-380 of 757) with videos related to

Sort By:
Pageof 76
Journal of the American Society of Nephrology : JASN|August 10, 2023
Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM)Norberto Perico, Giuseppe Remuzzi, Matthew D Griffin, et al.
Journal of the American Society of Nephrology : JASN|March 21, 2008
Role of remission clinics in the longitudinal treatment of CKDPiero Ruggenenti, Elena Perticucci, Paolo Cravedi, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress reportLuca Antiga, Marina Piccinelli, Giorgio Fasolini, et al.
Journal of the American Society of Nephrology : JASN|October 29, 2014
Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKDGerald Schulman, Tomas Berl, Gerald J Beck, et al.
Journal of the American Society of Nephrology : JASN|April 9, 2016
Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney DiseaseTobias F Kröpelin, Dick de Zeeuw, Giuseppe Remuzzi, et al.
Kidney International|August 8, 2002
Effect of angiotensin II antagonism on the regression of kidney disease in the ratAndrea Remuzzi, Elena Gagliardini, Chiara Donadoni, et al.
Lancet (London, England)|March 7, 2002
Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trialRaul Plata, Arturo Cornejo, Carla Arratia, et al.
American Journal of Nephrology|August 31, 2011
Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritisAlessandro Ble, Marta Mosca, Giorgio Di Loreto, et al.
Clinical and Experimental Nephrology|July 26, 2017
Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120Gerald Schulman, Tomas Berl, Gerald J Beck, et al.
Pageof 76